Nirmidas Biotech is Diagnostic Equipment in United States that focus on markets breakthrough business. Founded in 2013. They cover business area such as developer, diagnostic research technology, manufacture, market, breakthrough biological testing, imaging, a novel red, infrare fluorescence, detection platform, personal and portable diagnostic system, early disease diagnosis, prognosis monitoring, population-base screening.
2013
( 11 years old in 2024 )
Markets Breakthrough
-
2627 Hanover Street
Palo Alto, CA 94304
United States
Private
developerdiagnostic research technologymanufacturemarketbreakthrough biological testingimaginga novel redinfrare fluorescencedetection platformpersonal and portable diagnostic systemearly disease diagnosisprognosis monitoringpopulation-base screening
* We use standard office opening hours in near Nirmidas Biotech's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Nirmidas Biotech is Diagnostic Equipment business from United States that founded in 2013 (11 years old in 2024), Nirmidas Biotech business is focusing on Markets Breakthrough.
Nirmidas Biotech headquarter office and corporate office address is located in 2627 Hanover Street Palo Alto, CA 94304 United States.
Nirmidas Biotech was founded in United States.
In 2024, Nirmidas Biotech is currently focus on markets breakthrough sector.
Above is snippet of Google Trends for "markets breakthrough" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Nirmidas Biotech, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
